tetrofosmin
MYOVIEW 30ML (tetrofosmin) is (99mtc) tetrofosmin is a lipophilic, cationic complex which diffuses passively through the cell membrane and is locally retained actively due to the presence of intact mitochondria reflecting the presence of viable cells. First approved in 1996.
Drug data last refreshed 18h ago · AI intelligence enriched 2mo ago
MYOVIEW 30ML (tetrofosmin) is a radiopharmaceutical imaging agent containing technetium-99m that passively diffuses into myocardial cells and is retained by intact mitochondria in viable tissue. It is used for myocardial perfusion imaging to assess coronary artery disease and myocardial viability. The agent localizes according to blood flow and metabolic activity, providing diagnostic information about cardiac function and tissue health.
Product is at peak commercial stage with significant competitive pressure (8/10), suggesting mature market dynamics and established team structures.
(99mTc) tetrofosmin is a lipophilic, cationic complex which diffuses passively through the cell membrane and is locally retained actively due to the presence of intact mitochondria reflecting the presence of viable cells. After intravenous injection, it is distributed within the myocardium…
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
LOE in ~4 years — strategic planning for patent cliff underway
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.
Working on MYOVIEW positions you in a mature, stable cardiac imaging franchise with established market dynamics and commercial infrastructure. Career growth emphasizes commercial optimization, market defense, and preparation for post-LOE transition strategies.
Upgrade to Pro to access patent cliff timelines and LOE dates and other premium pharma intelligence.
Upgrade to Pro — $25/mo